1	Title:
2	Development and Validation of the Cannabis Exposure in Pregnancy Tool (CEPT)
3	
4	Kathleen H. Chaput PhD ^{1,2} , Carly A. McMorris PhD ³ , Amy Metcalfe PhD ^{1,2} Catherine Ringham
5	PhD, Stephen Wood MD ¹ , Deborah McNeil PhD ^{2,4} , Shaelen Konschuh MSc ⁶ , Laura Sycuro PhD ^{1,6} ,
6	Sheila W. McDonald PhD ^{2,5}
7	
8	1. Department of Obstetrics and Gynecology, Cumming School of Medicine, University of
9	Calgary
10	2. Department of Community Health Sciences, Cumming School of Medicine University of
11	Calgary
12	3. Werklund School of Education, School and Child Psychology, University of Calgary
13	4. Maternal Newborn Child and youth Strategic Clinical Network, Alberta Health Services
14	5. Research and Innovation Population, Public, and Indigenous Health, Alberta Health Services
15	6. Department of Microbiology, Immunology and Infectious Diseases, Cumming School of
16	Medicine, University of Calgary
17	
18	Correspondence:
19	Kathleen H. Chaput
20	1403 29 Street NW
21	Calgary, Alberta, T2N 2T9
22	Phone: 1-403-944-4009; email:khchaput@ucalgary.ca

- 23
- 24 Funding statement: This project was funded by a competitive research grant from the Alberta
- 25 Children's Hospital Research Institute, University of Calgary.
- 26 **Competing interests:** No Authors have competing interests to declare.
- 27 Word count: 3011

28 Abstract: (248 words)

29	Background: Evidence of associations between prenatal cannabis use (PCU) and maternal and
30	infant health outcomes remains conflicting amid broad legalization of cannabis across Canada
31	and 40 American states. A critical limitation of existing evidence lies in the non-standardized
32	and crude measurement of PCU, resulting in high risk of misclassification bias. We developed a
33	standardized tool to comprehensively measure prenatal cannabis use in pregnant populations
34	for research purposes.
35	Methods: We conducted a patient-oriented tool development and validation study using a
36	bias-minimizing process. Following an environmental scan and critical appraisal of existing
37	prenatal substance use tools, we recruited pregnant participants via targeted social media
38	advertising and obstetric clinics in Alberta, Canada. We conducted individual in-depth
39	interviews and cognitive interviewing in separate sub-samples, to develop and refine our tool.
40	We assessed convergent and discriminant validity internal consistency and 3-month test-retest
41	reliability, and validated the tool externally against urine THC bioassay.
42	Results: 254 pregnant women participated. The 9-item Cannabis Exposure in Pregnancy Tool
43	(CEPT) had excellent discriminant (Cohen's kappa=-0.27-0.15) and convergent (Cohen's
44	kappa=0.72-1.0) validity; as well as high internal consistency (Chronbach's alpha = 0.92), and
45	very good test-retest reliability (weighted Kappa=0.92, 95% C.I. [0.86-0.97]). The CEPT is valid
46	against urine THC bioassay (sensitivity=100%, specificity=77%).
47	Interpretation: The CEPT is a novel, valid and reliable measure of frequency, timing, dose, and
48	mode of PCU, in a contemporary sample of pregnant women. Using CEPT (compared to non-

- 49 standardized tools) can improve measurement accuracy, and thus the quality of PCU and
- 50 maternal and child health research.
- 51
- 52

53 Background:

54	Admist a backdrop of cannabis legalization, prenatal cannabis use (PCU) is rising (1,2). Despite
55	recent studies showing associations between PCU and adverse maternal, infant, and child
56	outcomes (3–6), the evidence remains conflicting (7–12). A critical limitation of published
57	studies is a high risk of misclassification bias resulting from a lack of standardized measurement
58	of PCU across adequate domains, including frequency, dose, modes, timing of use in pregnancy,
59	and second-hand smoke and vapour. There is an urgent need for high-quality cannabis-related
60	health research, and pregnant individuals and infants have been identified as priority
61	populations (9,10,13). Improved measurement of PCU in research is a key component to
62	improving the quality of the evidence.
63	
64	Current PCU measurement options available for research include administrative data collected
65	during routine prenatal care, substance use disorder (SUD) screening tools, non-validated
66	questionnaires, and biological tests. Administrative data is problematic for research use
67	because pregnant people are known to under-report prenatal substance use to physicians
68	(14,15). Further, PCU screening is not standardized practice, occurs variably, and is seen as low-

69 priority for the majority of obstetricians (16). While Canadian studies using administrative data

70 have reported PCU prevalence between 2% and 3% (2–4), emerging evidence from an

71 *anonymous* population-based survey indicates an 11% prevalence of PCU (17). In a US study

only 36% of women with cannabis-positive urine tests had reported their use to a care provider

73 (18), indicating that the majority of prenatal cannabis users may be misclassified in

74 administrative data studies.

75	While self-administered research questionnaires can garner more accurate reporting of
76	substance (e.g. alcohol) use in pregnancy than screening in clinical settings (19,20), non-
77	standardized survey questions have limited utility for measurement of PCU, as they can
78	unintentionally convey perceived bias against PCU. They often identify cannabis as an illicit drug
79	and do not differentiate between medicinal and recreational use, which contradicts social
80	perception and may increase response bias (18,21). Survey questions are problematic for
81	studying nuanced associations with maternal and infant health outcomes due to inconsistent
82	assessment of frequency and timing of use, including changing patterns through pregnancy,
83	and often lack dose measurement, or use subjective dose-terminology (9,10,22–28). Further,
84	most lack measurement of potentially important consumption modes aside from smoking
85	(vapourized, edible, topical, second-hand)(22–24). Standardized SUD screening tools aim to
86	detect a diagnosable SUD, and do not measure patterns PCU throughout pregnancy (29). Many
87	screen for alcohol misuse alone (30–33), or combine all drugs into a single category (29)
88	preventing the separate evaluation of cannabis-related health outcomes. Biological
89	(urine/blood/saliva) cannabis-screeners exist, but are limited to detection within 1-5 weeks of
90	use, depending on individual metabolism and test cut-off levels (34–38). Biological samples are
91	also resource-intensive and stigmatizing to collect, limiting their utility for prospective research.
92	Our study developed and validated a novel PCU measurement tool, that addresses the
93	limitations of current measurement methods, using a patient-oriented approach to identify
94	patient-perceived stigma, and reduce perceived sources of response bias, using a six-step, peer-
95	reviewed process (39).

97 Methods:

98 We recruited pregnant, past- and current-cannabis users and non-users, between 08/2019 and 99 04/2020 for the mixed-methods tool development phase and an external validation cohort 100 between 04/2022 and 12/2022. We used social media advertising targeted to women aged 18-101 45 years, residing in Alberta, with listed interests or group memberships related to pregnancy, 102 parenting, and/or cannabis, and posted gender-neutral recruitment ads in an online trans-103 gender parent support group. Study recruitment letters were also mailed to patients who 104 visited Alberta Health Services (AHS) clinics for pregnancy-related care in the preceding six 105 months, identified using pregnancy-related codes in the National Ambulatory Care Reporting 106 System (NACRS)(Appendix A). We included participants meeting target criteria who were <36 107 weeks' gestation at intake. Our target development sample size of 150 participants was 108 sufficient to detect a Cronbach's alpha of >0.9, with 95% confidence for test-retest reliability on 109 a tool that contains up to 15 items (39), and our external convenience sample of 85 participants 110 was feasible for conducting urine THC bioassays with available resources. This study was 111 approved by the Conjoint Health Research Ethics Board at the University of Calgary (REB19-112 0670), and written informed consent was obtained from all participants. 113 Step 1 Qualitative Interviews: We conducted individual in-depth interviews with 10 regular and 114 occasional cannabis users, and non-users, purposively selected from the full sample (Figure 1). 115 Two research assistants with gualitative interview training conducted telephone interviews at a 116 time chosen by the participant, about views and experiences with cannabis use in general, and 117 during pregnancy. Prior to interviews, research staff contacted participants twice to discuss 118 study details, including confidentiality, and establish a trusting relationship, by disclosing their

119	own connections to the study topic, emphasizing a non-judgmental approach, and
120	acknowledging all experiences shared were important. We recorded and transcribed interviews
121	verbatim, and used deductive thematic analysis to extract pre-determined themes of: language
122	around cannabis and its use; perceptions of stigma and judgement, and their relationships to
123	truthful disclosure of use; patterns of use in pregnancy (timing, frequency of use, typical dose);
124	motivations for use; and forms of cannabis used. Two team members experienced in qualitative
125	methods coded salient content that corresponded to the pre-determined themes, collapsed
126	codes into broader themes using constant comparison technique, discussion and consensus.
127	Themes were then reported back to the qualitative participants via email for member-checking
128	of the relevance and appropriateness to ensure truth value.
129	Step 2 Devising Items: We devised items, including wording, to draft the tool based on
130	strengths and shortcomings identified in existing SUD tools and published survey questions
131	(Table 1), and on themes identified from interviews. We eliminated double-barreled questions,
132	ambiguous wording and ensured a 6th grade reading level.
133	Step 3 Cognitive interviewing and bias reduction: Schwartz and Oyserman (40) propose five
134	stages of cognition required to accurately self-report behaviour, each of which are susceptible
135	to bias: 1. question understanding, 2. recalling relevant behaviour, 3. inference & estimation, 4.
136	mapping answer onto response options, and 5. answer editing. To identify points of bias at all
137	five stages of cognition, we conducted individual cognitive interviews with an additional sub-
138	sample of participants from the full sample, in which respondents were asked to think aloud,
139	and share impressions, understanding, and reasoning related to each of the five stages of
140	cognition, as we administered the newly developed tool (41). We iteratively revised items

141 according to participant feedback prior to each subsequent interview, until no new suggestions

142 for revision were made in two consecutive interviews (after interview 17).

143 Step 4 Content Validation: We then formatted the refined items into the CEPT online tool,

144 compared to our critical apporaisal of existing tools to ensure it captured all domains of

145 measurement that are critical to prospective research cannabis in pregnancy, including timing,

146 multiple modes of consumption, dose per use and frequency of use.

147 Step 5 Convergent and Discriminant Validation: We then administered the finalized CEPT, along

148 with the SURP-P(42) and 4Ps+ (30) SUD screening tools via electronic questionnaire, to our

remaining sample of 150 women. We measured concurrent validity of CEPT responses against

150 detailed cannabis use information revealed during the interviews using Cohen's weighted

151 kappa. There is strong evidence that a high degree of truth value can be achieved with rigorous

152 qualitative interview techniques.(43) We assessed discriminant validity of CEPT responses

against SURP-P and 4Ps+ tools using Cohen's kappa. We calculated internal consistency on all

154 CEPT cannabis consumption items using Chronbach's alpha, acknowledging that it measures

155 multiple constructs of cannabis exposure (i.e. any use, frequency, timing, dose, mode and

156 reasons), rather than a single construct. However, we anticipated internal consistency among

157 the CEPT items, as a person indicating use should have non-zero responses for dose, mode

158 frequency and reasons for use. We then re-administered the tool to all development-phase

participants (n=150) 3 months later to assess test-retest reliability using a weighted Cohen's
kappa (Figure 1).

Step 6 External validation: In an additional external sample of 84 pregnant participants, we
 validated CEPT responses against urine bioassay measurements of 11-nor-9-carboxy-Δ⁹- THC,

163	the most abundant THC metabolite (Figure 2). Participants provided urine samples in sterile
164	collection containers that were shipped frozen to our laboratory by pre-paid courier for
165	analysis, within 24 hours of completing an online questionnaire including the CEPT. We stored
166	samples at -80°c until analysis. 2ml aliquots were taken from thawed samples, centrifuged and
167	diluted (10x) with ultrapure water and assayed in duplicate using a 96-strip-well, THC
168	Metabolite ELISA Kit (catalogue # 701570, Cayman Chemicals [™] , United States of America)
169	according to manufacturer's protocol. No freeze-thaw cycles were allowed, and the lowest
170	threshold of THC positivity detectable by the kits (0.072 η g/ml) was used to classify those with
171	PCU versus those without.

172 <u>Results:</u>

Our sample included 254 pregnant past, current, and non-consumers of cannabis, 170 in the
development phase and 84 in the external validation cohort. Specific sub-samples participated
in various steps (Figures 1,2). Table 2 summarizes participant characteristics at enrollment.
Other sociodemographic characteristics of our sample were similar to the overall maternal
population in Canada (44–46). (Fig. 3)

178 **Qualitative interviews:**

We completed qualitative data collection after 10 interviews, when we reached thematic saturation (no new themes emerged). Summaries of deductive themes and illustrative quotes are presented in Table 3. Interviews informed bias-minimizing language and wording, tool structure, and appropriate response options for frequency dose and reasons for use. Themes drove the terminology and language used in the tool preamble and questions, guided tool structuring including inclusion of specific items (e.g. reasons for use) and response options, and

185 determined the method of dose measurement. While legalization was perceived to have 186 reduced stigma around cannabis use in general, perceptions of stigma against prenatal use 187 were prevalent and thus important for consideration to encourage accurate disclosure. Several 188 participants noted that including a response option to disclose cannabis consumption that 189 occurred only prior to pregnancy recognition was crucial, and noted if this option was not 190 present, they would not report use, even if they had consumed cannabis prior to pregnancy recognition. A challenging aspect of cannabis consumption measurement is identifying dose. IDI 191 192 results identified a reliable method of quantifying approximate dose per use (i.e. comparing 193 amounts to common objects, like food items or coins). Approximate THC/CBD content can be 194 inferred based on mean THC content of dried cannabis available on the contemporary market 195 (24%)(47), or the labeled concentration of products as reported by participants. (Supplementary 196 file 2)

197 **Cognitive interviews:**

We completed cognitive interviews with a separate sub-sample of 17 participants to assess and minimize points of bias through participant-led refinement (Figure 4). This resulted in 9 sequential iterations of our initial draft tool. Perceived sources of bias at all five stages of cognition were identified, and changes made based on participant feedback.

202 *Question understanding*: Most draft-tool questions were well understood; however, some 203 changes were made to improve clarity.

204 *Recalling relevant behaviour*: All participants indicated they were accurately able to recall

205 details of first-hand cannabis consumption, including frequency, trimester of consumption,

reasons, modes, and amounts per use. Nearly all participants (93%) indicated they were able to

accurately recall the details of second-hand cannabis smoke or vapour exposure, aside from
brief outdoor exposures. We amended the second-hand exposure question to include exposure
while in the same room as the user.

210 Inference & estimation: Participants did not express concerns about inference or estimation on

211 items measuring any consumption/exposure, or frequency, timing or reasons for use. Dose

212 questions were adjusted to address perceived ambiguity and aid with estimation (Figure 4).

213 Mapping answers onto response options: Several participants noted problems with initial dose-

214 per-use options, increments for some product types were deemed too large for use in

215 pregnancy, and we refined categories to align with appropriate ranges and increments.

216 Answer editing: No participants expressed the need to edit responses once the above

217 clarifications and response-option edits had been made. Participants agreed the tool was non-

218 judgemental, appropriate, and acceptable to them in pregnancy, and that it would elicit truthful

responses, confirming face and content validity from the participant perspective.

220 The final CEPT has 9 items measuring weeks of gestation, second-hand exposure, partner use,

trimester(s) of use, frequency, reasons, modes of consumption, and dose per use for each

222 mode indicated. Frequency, reasons, modes, and dose items repeat for each trimester of use

223 indicated. (Appendix A)

224 Validity and reliability:

Concurrent validity was excellent, with agreement between IDI participant CEPT responses and
use reported in IDIs, ranging from 80% to 100%, and kappa values ranging from substantial
(0.72) to perfect (1.0) (49) (Table 4). The timing of use construct showed the lowest level of
agreement, which was expected. Use will be reported in more trimesters as a pregnancy

229 p	progresses. A gr	reater pro	portion of j	participa	ants (4	40%)	reported	third-trime	ster use	on the
-------	------------------	------------	---------------------	-----------	---------	------	----------	-------------	----------	--------

- online CEPT, compared with IDIs (30%), which occurred 5-6 weeks prior. Discriminant validation
- 231 indicated poor agreement between two pregnancy SUD screening tools (5ps and the SURP-
- p)(33), with weighted Kappa values ranging from -0.31 to 0.36 indicating that the CEPT

233 measures different constructs from those on the existing tools. (Table 5)

- 234 Reliability testing showed excellent internal consistency (Chronbach's alpha=0.92) and
- substantial to near-perfect Kappa values (0.71-0.99) for test-retest reliability (Table 6). Although

some patterns of use may be expected to change throughout pregnancy, the strong agreement

- 237 between early and late pregnancy responses on the CEPT support that recall of cannabis
- 238 consumption using this tool is reliable up to delivery.
- 239 CEPT-reported cannabis use was valid against urine-THC bioassay with 100% sensitivity, and
- 240 77% specificity, indicating that it has promise as an improved measure of PCU for research
- purposes (Table 7). All participants with positive urine bioassay disclosed cannabis use within 1
- 242 week of the urine sample being collected, indicating that the time elapsed since last use was
- the main driver of lower specificity.

244 Interpretation:

The CEPT addresses the measurement limitations faced by previously published studies of PCU and maternal and infant health, which are highly susceptible to misclassification bias, have inconsistent findings, and are rated moderate at best by the US National Academies of Science Engineering and Medicine(10,50). It offers researchers a measurement option with strong validity and reliability, that accounts for frequency, modes, reasons and estimated dose-peruse, separately measures CBD and THC, and allows repeated measures per trimester to capture

251 changing patterns of PCU. It alos measures frequency and timing of second-hand exposure, in addition to partner's cannabis use. The CEPT thus enables more complete picture of exposure 252 253 over pregnancy than currently published studies have been able to capture. The patient-254 oriented methods we used are a strength; qualitative interviews can reveal aspects of health behaviour that contrast with the researcher's underlying assumptions, that can interfere with 255 256 the five stages of cognition leading to biased response (39,40). Prenatal alcohol use studies 257 indicate that non-disclosure bias for prenatal substance use varies according to participant 258 perceptions, and that question wording and structure informed by patient-oriented designs can 259 improve validity (20,51). Further, the language, tone, and perceived intent of the tool are 260 critical to non-biased response. Our qualitative interviews guided us in reducing perceived 261 judgemental or stigmatizing language in our tool. The cognitive interviews further reduced 262 sources of bias. While we may never be able to completely eliminate PCU reporting bias our 263 patient-oriented development process was chosen because it is crucial for minimising perceived 264 stigma, and ensuring a much lower probability of bias than the methods of measurement used 265 in previous studies, including self-selection for biological samples, which do not allow the 266 participant to explain their reasons for use, nor to judge the researachers' motivations. 267 Although there remains no feasible gold-standard measure of prenatal cannabis consumption 268 across the entire gestational period, the CEPT represents a useful tool for researchers to 269 augment the quality and expand the scope of longitudinal research into the health outcomes 270 associated with prenatal cannabis exposure. Our results support that it minimizes self-report 271 bias, and its nuanced measurement of multiple dimensions of cannabis consumption may also 272 reduce misclassification of very low exposures, allow for assessment of potential dose-response

273 relationships, and enable the identification of critical windows of fetal exposure in future

274 studies, that were not possible with previous crude measures.

275 *Limitations:* The CEPT is designed to measure behaviours over pregnancy, rather than to detect 276 a condition or health state. Where medical screening tools can be validated against diagnostic 277 tests or interview, validating a measure of behaviour is more complex. A limitation of our study 278 is the lack of a true gold-standard measure of PCU for validation, which was financially 279 infeasible for this study, as it requires multiple bioassays of at least weekly serial urine samples 280 throughout gestation. However, we have preliminarily validated CEPT responses against a 281 biological reference-standard, showing excellent sensitivity and high specificity. While we could 282 not attain a true biological gold-standard in our study, the validation we conducted against 283 single bioassays, and in-depth qualitative interviews remains rigorous. Biological levels of THC 284 metabolite cannot be falsified, and the qualitative methods we employed result in high 285 credibility and truth-value for gualitative results (57). Further, interviews allowed for 286 comparison of binary cannabis use as well as PCU patterns (modes, frequency, timing) that 287 cannot be validated with a biological test. Although our study sample was adequate to detect a 288 Cronbach's alpha of >0.9 on a tool with up to 15 items, we acknowledge that our external 289 bioassay validation sample (n=84) was small. Future validation studies should include larger 290 samples to confirm findings. It is also important to note that our tool and the validation 291 conducted are limited to English-speaking individuals, and translations will require further 292 validation.

293 Conclusion:

294	PCU and its associated health outcomes have been identified as priorities for research in
295	Canada and the U.S. following cannabis legalization (9). We recommend the CEPT as a rigorous,
296	feasible, patient-oriented health research tool for measuring PCU. The use of the CEPT as a
297	standardized measure of PCU in future studies can contribute substantial new knowledge about
298	the implications of timing, dose, frequency, and modes of exposure for maternal, fetal, infant
299	and child health, accounting for varying patterns of consumption and the strength and diversity
300	of cannabis products available on the contemporary legal market. The CEPT has the potential to
301	significantly improve measurement accuracy and thus the quality of research in this area, which
302	can in turn inform evidence-based education, prevention and health policy to mitigate potential
303	health risks.
304	
305	Data sharing: Quantitative data can be made available in accordance with the ethics approval

- 306 for the study, on reasonable request to the corresponding author.
- 307

Includes measure of:	4ps	4ps+	WIDUS	CRAFFT	SURP-P	StatsCan	Generation-R	NSDUH
Cannabis separately	no	no	no	yes	yes	yes	yes	yes
Use in pregnancy	no	yes	no	No	no	no	yes	*indirect
Frequency of use	no	no	no	no	no	yes	yes	yes
Timing of use in pregnancy	no	no	no	no	no	no	1 st trimester & pre-preg.	*indirect
Dose	no	no	no	no	no	yes	no	no
Mode of consumption	no	no	no	no	no	yes	no	no
Medicinal vs. recreational use	no	no	no	no	no	yes	no	no
Time-span covered	Past ever	Past month	Past ever	Past 12 months	Past ever	Past 3 months	Pre- pregnancy, First trimester	[*] Past 3 mos.
Second-hand exposure/partner use	yes	yes	yes	no	yes	no	yes	no
Reference	(29)	(30)	(31)	(32)	(33)	(44)	(5)	(50)

308 <u>Table 1: Measurement domains of existing prenatal cannabis measurement options</u>

4Ps=Parent drug problem, Partner drug problem, Past use of substance

4Ps+= Parent drug problem, Partner drug problem, Past use of substance, Pregnancy use

311 WIDUS= Wayne Indirect Drug Use screener; CRAFFT = Car, Relax, Alone, Forget, Friends, Trouble;

312 SURPP= substance use risk in pregnancy profile; NSDUH = National Survey on Drug Use and

*Health; StatsCan = Statistics Canada * specific date can be cross-referenced with pregnancy*

information if provided

	Development	sample (N=170)	External Validation Sample (N=84)			
	Proportion	95% Confidence	Proportion	95% Confidence		
Variable	% (n)	Interval	% (n)	Interval		
Parity						
nulliparous	63 (107)	54.9 - 70.1	63(52)	53-72		
multiparous	37 (63)	29 - 45	37 (29)	28-47		
Maternal Age						
<35	81 (137)	*	67(56)	57-77		
>35	19(33)	*	32(26)	23-43		
Female gender	100 (170)		100 (84)			
Ethnicity						
Caucasian	84.1 (23)	77 - 89	79(64)	69-87		
Non-Caucasian	15.9 (121)	11 - 22	21(17)	13-31		
Home ownership						
Owns home	52 (88)	42 - 58	64(52)	55-73		
Rent/other	48 (82)	41 - 57	35(29)	27-45		
Marital Status						
Married/common-law	78 (133)	77 - 79	89(75)	82-95		
other	22 (38)	18 - 26	11(9)	4-17		
Annual Household						
Income						
< \$60,000	59	52 - 67	12(10)	7-20		
\$60,000 or more	41	33 - 48	88(74)	80-93		
	Mean	Range	Mean	Range		
Gestational age	27 weeks	8-36 weeks	25 weeks	10-41 weeks		
Maternal age	*	*	32.4 years	21-42 years		

321 <u>Table 2: Participant Characteristics at Enrollment</u>

323

324

325 <u>Table 3: Deductive themes and illustrative quotes (n=10)</u>

Theme 1 - Language/wording: Participants indicated that non-judgemental wording around cannabis use						
as well as specific terms and context affected their choice to disclose their cannabis use while pregnant.						
"say "cannabis" instead of marijuana, because I think of marijuana only being the plant not						
edibles, or cbd and lip balm, or whatever."						
"Why you want to know is important. I would be way more up-front if I know it's for research, than						
like, if they want to know at the hospital"						
"If someone sounds judgmental, that would make me not want to discuss it. If it's something that it's						
clear that they're open to it, I would be like, yeah, here's how I take it and why."						
"I wouldn't say 'use', I would say 'consume'. [use] has a bit of a negative to it."						
"[marijuana] sometimes has a negative connotation, like it's a drug, but cannabis is more like it's						
natural."						

^{322 *}age only available categorically

Theme 2a) Teal structure. Constal: The need for non-independental wording, and for conschipt to be
Theme 2a) Tool structure - General: The need for non-judgemental wording, and for cannabis to be
treated separately from other substances on a questionnaire were identified as essential to avoid biased
responses.
"Say something at the beginning to make it clear that you're not judging. If it sounds judgmental, or
like, if I think you're asking me so you can lecture me someone's judging me for using it, I wouldn'
answer."
"I feel like if doctors were a little non-judgmental and a little less biased, then it would create some
more honesty."
"If it's lumped in with, you know, smoking, then drinking, then marijuana, thenheroin and cocaine, that just gives it a real negative tone like, it's worse than alcohol, and almost as bad as heroin I wouldn't be answering, really, if it's like that."
"it makes more sense to me to have it with supplements, or alternative therapies."
Theme 2b) Tool structure - Response options: Allowing participants to indicate their reasons for
consuming cannabis in pregnancy (which were predominantly reported as medicinal), was perceived as a key
factor for encouraging honest disclosure. A response option indicating that use only took place prior to
pregnancy recognition was also seen as essential to unbiased reporting.
"I believe the stigma has died a lot. But there is still a big stigma with pregnancy for some people."
"Especially in the first pregnancy women feel a lot more judged."
"I don't believe it should be used in pregnancy to get stoned, or to get high. But I believe that if it's going to help with morning sickness, or relieve pain, or anything that you're going through that may cause you suffering or stress, I believe it safe to use"
"some people stop as soon as they find out [they're pregnant], so you need to be able to say that."
Theme 3a) Patterns of use – Mode of consumption: Participants indicated numerous modes of
consumption (vapour, oral/edible, topical, cannabidiol (CBD)) with varying doses for each, and some
perceived as safer in pregnancy than others, supporting the need for standardized measurement of
consumption-routes beyond smoking.
"I would think that ingesting it would be a lot safer [than smoking] because there's less transfer to
the fetus."
"I think edibles and lotions and liquid CBD capsules even, they're most likely more safe to take during
pregnancy considering just that you're taking out the smoking out of the equation"
"I don't necessarily think that smoking it is the smartest."
"I mostly smoke, but I have drops and a lotion too."
" for vaping it, [I] stick to three puffs maximum when it comes to THC products."
"Smoking does work quite quickly, especially for morning sickness. But a tincture can work"
"I consume CBD oil daily, as well as smoking [cannabis]."
Theme 3b) Patterns of use - Frequency and Timing: Participants consistently indicated their patterns of
use changed during pregnancy to a more frequent consumption of smaller amounts, compared to their
general use pre-pregnancy, indicating that tool response options need to include high frequencies (i.e. multipl
times per day) and small dose-per-use categories, compared to existing survey questions.
"I use it different (sic) now that I'm pregnant I have a quick drag whenever I need it, so 3 or 4 times
a day sometimes, but just a tiny bit, instead of having a lot at once."
"I resumed micro-dosing daily"
"I think asking about frequency makes sense - most people use it pretty regular (sic)"
Theme 3b) Patterns of use – Dose: Amounts of cannabis typically consumed at each sitting was discussed primarily in subjective terms (i.e. large, small), perceptions of which may vary considerably between
consumers, and identifying the weights or exact doses used at each sitting was perceived as difficult or infeasible particularly for dried cannabis. Comparison measures were preferred
infeasible, particularly for dried cannabis. Comparison measures were preferred.
"I know how much I buy by weight, but I couldn't tell you the grams I put in the pipe yesterday
evening"
"With smoking it, it's harder like, a big joint for me might not be big for my sister."
"It's easy if it's an edible, because it tells you on the label"

"The THC oil that I have is 30 milligrams per mil, so that would work out to being about point three milligrams for point one or point two of a milliliter." "Maybe start at half a milliliter, so that would be what? More like 10 milligrams, I guess, of the 40 milligram [per milliliter] stuff that I have." "I would say the easiest way for people to say how much they smoke would be like a pea-sized amount, or a grape-size...compare it to something. Then you could figure out the grams from that. I don't know how many grams or milligrams I use every time." "I might use a small dab like the size of a dime, or other times it might be like twice as much..."

326

327

328 Table 4: Concurrent validity of the CEPT vs. In-depth interview (n=10)

	Agreement		Карра	Std. Error	P-Value	
Construct	actual	expected				
Any use in pregnancy	100%	82%	1.00	0.31	>0.001	
Frequency of use	90%	22%	0.87	0.16	>0.001	
Timing (trimester)	80%	28%	0.72	0.19	>0.001	
Mode of consumption	100%	22%	1.00	0.21	>0.001	

329

330 Table 5: Discriminant validity of CEPT versus SUD screening tools (n=153)

	CEPT Ag	reement	Карра	Std. Error	P-Value
Screening Tool	actual	expected			
5Ps	44.9%	45.1	-0.031	0.04	0.53
SURP-P	69.8%	52.3%	0.36	0.08	0.01

331 Legend: Compares positive SUD screening result with any PCU on CEPT


332 Table 6: Test-retest reliability of the CEPT - 3-month interval (n=153)

-	Agreement		Карра	Std. Error	P-Value	
Construct	actual	expected				
Any second-hand exposure	92%	52%	0.83	0.08	>0.001	
Any use in pregnancy	97%	51%	0.95	0.08	>0.001	
Frequency of use	90%	28%	0.86	0.04	>0.001	
Timing (trimester)	80%	32%	0.71	0.05	>0.001	
Mode of consumption	99%	51%	0.97	0.08	>0.001	


335 <u>Table 7: External Validation</u>

	Bioassay +	Bioassay -	Total
CEPT use "yes"	10	13	23
CEPT use "no"	0	61	61
Total:	10	74	84
	Value	95% Confid	ence interval
Sensitivity	100.0%	100.0%	- 100.0%
Specificity	82.43%	74.29%	90.57%
Positive predictive value	43.48%	32.88%	54.08%
Negative predictive value	100%	100.0%	- 100.0%


340341 Figure 1: Study Flow Diagram: Development phase



343 Figure 2: Study Flow Diagram – External Validation








350 Figure 4: Cognitive Interviews - Bias reduction for the five stages of cognition

351 <u>References:</u>



352

- 1. Young-Wolff KC, Sarovar V, Tucker LY, Avalos LA, Alexeeff S, Conway A, et al. Trends in
- 355 marijuana use among pregnant women with and without nausea and vomiting in
- 356 pregnancy, 2009–2016. Drug Alcohol Depend. 2019;196:66–70.
- 2. Corsi DJ, Hsu H, Weiss D, Fell DB, Walker M. Trends and correlates of cannabis use in
- 358 pregnancy: a population-based study in Ontario, Canada from 2012 to 2017. Can J Public
- Heal Can Sante Publique. 2018;Nov 1.
- 360 3. Luke S, Hutcheon J, Kendall T. Cannabis Use in Pregnancy in British Columbia and
- 361 Selected Birth Outcomes. J Obstet Gynaecol Canada. 2019;
- 362 4. Corsi DJ, Walsh L, Weiss D, Hsu H, El-Chaar D, Hawken S, et al. Association between Self-
- 363 reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. JAMA
- 364 J Am Med Assoc. 2019;
- 365 5. El Marroun H, Tiemeier H, Steegers EAP, Jaddoe VW V, Hofman A, Verhulst FC, et al.
- 366 Intrauterine Cannabis Exposure Affects Fetal Growth Trajectories: The Generation R
- 367 Study. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1173–81.
- 368 6. Marroun H El, Hudziak JJ, Tiemeier H, Creemers H, Steegers EAP, Jaddoe VWV, et al.
- 369 Intrauterine cannabis exposure leads to more aggressive behavior and attention
- 370 problems in 18-month-old girls. Drug Alcohol Depend. 2011;
- 371 7. Stickrath E. Marijuana Use in Pregnancy: An Updated Look at Marijuana Use and Its
 372 Impact on Pregnancy. Clin Obstet Gynecol. 2019;
- 8. Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: A review of the
- evidence. Vol. 213, American Journal of Obstetrics and Gynecology. 2015. p. 761–78.
- 9. Porath-Waller AJ. Clearing the Smoke on Cannabis Series: Maternal Cannabis Use during

376 Pregnancy. Can Cent Subst Abus. 2015;1–8.

- 377 10. Board on Population Health and Public Health Practice, Health and Medicine Division,
- 378 National Academies of Sciences Engineering and Medicine. The Health Effects of
- 379 Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for
- 380 Research [Internet]. The Health Effects of Cannabis and Cannabinoids: The Current State
- 381 of Evidence and Recommendations for Research. 2017. 440 p. Available from:
- 382 http://www.ncbi.nlm.nih.gov/pubmed/28182367
- 383 11. Torres CA, Medina-Kirchner C, O'Malley KY, Hart CL. Totality of the Evidence Suggests
- 384 Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and
- 385 Critical Review. Front Psychol. 2020;
- 386 12. Chaput KH, Lebel CA, McMorris CA. Commentary: Totality of the Evidence Suggests
- 387 Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and
- 388 Critical Review. Front Psychol. 2020;tbd(e-pub).
- 389 13. Center for Behavioral Health Statistics and Quality. Results from the 2012 National
- 390 Survey on Drug Use and Health. 2013.
- 391 14. Roberts SCM, Nuru-Jeter A. Women's Perspectives on Screening for Alcohol and Drug
 392 Use in Prenatal Care. Women's Heal Issues. 2010;20(3):193–200.
- 393 15. Ernhart CB, Morrow-Tlucak M, Sokol RJ, Martier S. Underreporting of alcohol use in
 394 pregnancy. Alcohol Clin Exp Res. 1988;12(4):506–11.
- 395 16. Holland CL, Nkumsah MA, Morrison P, Tarr JA, Rubio D, Rodriguez KL, et al. "Anything
- 396 above marijuana takes priority": Obstetric providers' attitudes and counseling strategies
- regarding perinatal marijuana use. Patient Educ Couns. 2016;99(9):1446–51.

398	17.	Kaarid KP, Vu N,	Bartlett K, P	Patel T, Sharma S,	Honor RD, et al.	Assessing the prevalence
-----	-----	------------------	---------------	--------------------	------------------	--------------------------

- 399 and correlates of prenatal cannabis consumption in an urban Canadian population: a
- 400 cross-sectional survey. Can Med Assoc Open Access J [Internet]. 2021;9(2):E703--E710.
- 401 Available from: https://www.cmajopen.ca/content/9/2/E703
- 402 18. Chang JC, Holland CL, Tarr JA, Rubio D, Rodriguez KL, Kraemer KL, et al. Perinatal illicit
- 403 drug and marijuana use: An observational study examining prevalence, screening, and
- disclosure. Am J Heal Promot. 2017;31(1):35–42.
- 405 19. Hannigan JH, Chiodo LM, Sokol RJ, Janisse J, Ager JW, Greenwald MK, et al. A 14-year
- 406 retrospective maternal report of alcohol consumption in pregnancy predicts pregnancy
 407 and teen outcomes. Alcohol. 2010;44(7–8):583–94.
- 408 20. Chiodo LM, Sokol RJ, Delaney-Black V, Janisse J, Hannigan JH. Validity of the T-ACE in
- 409 pregnancy in predicting child outcome and risk drinking. Alcohol [Internet]. 2010/01/06.
- 410 2010;44(7–8):595–603. Available from: https://pubmed.ncbi.nlm.nih.gov/20053522
- 411 21. Rotermann M, Pagé MM. Prevalence and correlates of non-medical only compared to
- 412 self-defined medical and non-medical cannabis use, Canada, 2015. Heal Reports.
- 413 2018;29(7):3–13.
- 414 22. Singer LT, Arendt R, Fagan J, Minnes S, Salvator A, Bolek T, et al. Neonatal visual
- 415 information processing in cocaine-exposed and non-exposed infants. Infant Behav Dev.
- 416 1999;
- 417 23. Fried PA, Watkinson B. 36- and 48-month neurobehavioral follow-up of children
- 418 prenatally exposed to marijuana, cigarettes, and alcohol. J Dev Behav Pediatr. 1990;
- 419 24. Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, et al. Effect of

- 420 prenatal marijuana exposure on the cognitive development of offspring at age three.
- 421 Neurotoxicol Teratol. 1994;
- 422 25. el Marroun H, Tiemeier H, Jaddoe VWV, Hofman A, Mackenbach JP, Steegers EAP, et al.
- 423 Demographic, emotional and social determinants of cannabis use in early pregnancy: The
- 424 Generation R study. Drug Alcohol Depend. 2008;
- 425 26. Office of Research and Surveillance. Canadian Tobacco Alcohol and Drugs (CTADS): 2015
- 426 summary [Internet]. CTADS 2015. 2017. Available from:
- 427 https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-
- 428 survey/2015-summary.html
- 429 27. Coleman-Cowger VH, Schauer GL, Peters EN. Marijuana and tobacco co-use among a
- 430 nationally representative sample of US pregnant and non-pregnant women: 2005–2014
- 431 National Survey on Drug Use and Health findings. Drug Alcohol Depend. 2017;177.
- 432 28. Leos-Toro C, Rynard V, Hammond D. Prevalence of problematic cannabis use in Canada:
- 433 Cross-sectional findings from the 2013 Canadian Tobacco, alcohol and drugs survey. Can
- 434 J Public Heal. 2017;108(5–6):e516–22.
- 435 29. Gotman N, Kershaw T, Rounsaville BJ, Forray A, Howell HB, Yonkers KA. Screening for
 436 Prenatal Substance Use. Obstet Gynecol. 2010;116(4):827–33.
- 437 30. Chasnoff IJ, Wells AM, McGourty RF, Bailey LK. Validation of the 4P's Plus[©] screen for
- 438 substance use in pregnancy validation of the 4P's Plus. J Perinatol. 2007;27(12):744–8.
- 439 31. Ondersma SJ, Svikis DS, Lebreton JM, Streiner DL, Grekin ER, Lam PK, et al. Development
- 440 and preliminary validation of an indirect screener for drug use in the perinatal period.
- 441 Addiction. 2012;107(12):2099–106.

442 32. Harris SK, Knight JR, Van Hook S, Sherritt L, L Brooks T, Kulig JW, et al. Adolesc	442	32.	Harris SK, Knight JR	, Van Hook S, Sherritt L,	L Brooks T,	Kulig JW	, et al. Adolesce
--	-----	-----	----------------------	---------------------------	-------------	----------	-------------------

- substance use screening in primary care: Validity of computer self-Administered versus
- 444 clinician-Administered screening. Subst Abus. 2016;37(1):197–203.
- 445 33. Yonkers KA, Gotman N, Kershaw T, Forray A, Howell HB, Rounsaville BJ. Screening for
- 446 prenatal substance use: Development of the substance use risk profile-pregnancy scale.
- 447 Obstet Gynecol. 2010;116(4):827–33.
- 448 34. James WH, Moore DD. Examining the Relationship between Gender and Drug-Using
- 449 Behaviors in Adolescents: The Use of Diagnostic Assessments and Biochemical Analyses
- 450 of Urine Samples. J Drug Educ. 2005;29(3):235–49.
- 451 35. Mura P, Kintz P, Papet Y, Ruesch G, Piriou A. [Evaluation of six rapid tests for screening of
- 452 cannabis in sweat, saliva and tears]. Acta Clin Belg. 1999;53 Suppl 1:35–8.
- 453 36. Pippins JR, Brawarsky P, Jackson RA, FuentesAfflick E, Haas JS. Association of
- 454 Breastfeeding with Maternal Depressive Symptoms. J Women's Heal [Internet]. 2006
- 455 Jul;15(6):754–62. Available from: http://Haas, Jennifer S.: jhaas@partners.org
- 456 37. Riley KJ, Lu NT, Taylor BG. Drug screening: A comparison of urinalysis results from two

457 independent laboratories. J Drug Issues. 2000;30(1):171–86.

458 38. Earleywine M. Understanding Marijuana: A New Look at the Scientific Evidence.

- 459 Understanding Marijuana: A New Look at the Scientific Evidence. 2010. 1–341 p.
- 460 39. Streiner DL, Norman GR., John Cairney Health Measurement Scales: A Practical Guide To
- 461 Their Development and Use, January 2015 Edition: 5th Publisher: Oxford University Press
- 462 ISBN: 0199685215 DOI:10.1093/acprof:oso/9780199231881.003.0006,
- 463

- 464 40. Schwarz N, Oyserman D. Asking questions about behavior: Cognition, communication,
- and questionnaire construction. Am J Eval. 2001;22(2):127–60.
- 466 41. Willis G, Lessler J. Question Appraisal System (QAS 99 Manual). 1999.
- 467 42. Coleman-Cowger VH, Oga EA, Peters EN, Trocin K, Koszowski B, Mark K. Comparison and
- 468 validation of screening tools for substance use in pregnancy: A cross-sectional study
- 469 conducted in Maryland prenatal clinics. BMJ Open. 2018;8(2).
- 470 43. Sale J, Brazil K. A strategy to identify critical appraisal criteria for primary mixed methods
- 471 research. Qual Quan. 2004;38:351–65.
- 472 44. Canada. PHA of. Data Tables The Maternity Experiences Survey (MES) 2006 2007
- 473 [Internet]. Vol. 2012. 2009. Available from: http://www.phac-aspc.gc.ca/rhs-ssg/pdf/tab-
- 474 eng.pdf
- 475 45. Teubert D, Pinquart M, Pinheiro MIS, Haase VG, Del Prette A, Amarante CLD, et al. NIH
- 476 Public Access. Eur J Psychotraumatol [Internet]. 2015;15(1):No-Pagination Specified.
- 477 Available from: http://www.repositorio.ufc.br/bitstream/riufc/7744/1/2014-DIS-
- 478 ASMGRANGEIRO.pdf%0Ahttp://files/5407/GRANGEIRO,
- 479 2014.pdf%0Ahttp://files/5404/rocha, marina teses
- 480 ysr.pdf%0Ahttp://linkinghub.elsevier.com/retrieve/pii/S0890856716302167%0Ahttp://fil
- 481 es/5400/ache
- 482 46. No Title [Internet]. Vol. 2019. 2019. Available from:
- 483 https://www.nbs.go.tz/index.php/en/census-surveys/population-and-housing-
- 484 census/178-tanzania-total-population-by-district-regions-2016-2017
- 485 47. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis

- 486 potency over the last 2 decades (1995-2014): Analysis of current data in the United
- 487 States. Biol Psychiatry. 2016;
- 488 48. Niedbala S, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ. Passive cannabis
- 489 smoke exposure and oral fluid testing. J Anal Toxicol. 2004;
- 490 49. Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data.
- 491 Biometrics [Internet]. 1977 Jun 22;33(1):159–74. Available from:
- 492 http://www.jstor.org/stable/2529310
- 493 50. The National Academies of Science Engineering. The health effects of Cannabis and
- 494 Cannabinoids. Committee's conclusions. The National Academies of Science Engineering
- 495 and Medicine. Natl Acad Press [Internet]. 2018; Available from:
- 496 http://www.dictionary.com/browse/weight
- 497 51. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: Practical prenatal detection of risk-
- 498 drinking. Am J Obstet Gynecol. 1989;160(4):863–70.
- 499 52. De Giovanni N, Fucci N. The Current Status of Sweat Testing For Drugs of Abuse: A
- 500 Review. Curr Med Chem. 2013;20(4):545–61.
- 501 53. Berg M. Status of research on gender differences in pharmacokinetics. J Am Pharm
- 502 Assoc. 1997;37:43–56.
- 503 54. Harris R, Benet L, Schwartz J. Gender effects in pharmacokinetics and
- 504 pharmacodynamics. Drigs. 1995;50:222–39.
- 505 55. Mattison D, Malek A, Cistola C. Physiologic adaptations to pregnancy: Impact on
- 506 pharmacokinetics. In: Yaffe S, Aranda J, editors. Pediatric Pharmacology: Therapeutic
- 507 principles in practice. Philidelphia: W.B. Saunders; 1992. p. 81–96.

508	56.	Amon I, Huller H. Dose-response relationship as a basis for choice of drugs in pregnancy
509		and for dosage calculation. In: Kuemmerle H, Brendel K, editors. Clinical pharmacology in
510		pregnancy: Funda- mentals and rational pharmacotherapy. Nwe York: Thieme-Stratton;
511		1984. p. 64–73.
512	57.	Lincoln Y, Guba NJ. Naturalistic inquiry. Vol. 1. Beverly Hills: Sage Publications; 1985.
513		